Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor

Endocrinology

Volumn 153, Issue 10, 2012, Pages 5090-5100

  Zhao, Li ^a   Zhu, Xuguang ^a   Park, Jeong Won ^a   Fozzatti, Laura ^a   Willingham, Mark ^b   Cheng, Sheue Yann ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE; PROPYLTHIOURACIL; PROTEIN TYROSINE KINASE; THYROID HORMONE RECEPTOR BETA; THYROTROPIN; TRANSCRIPTION FACTOR E2F1;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE MUTATION; HETEROZYGOSITY; HORMONE ACTION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CARCINOMA; THYROID FOLLICLE CELL; THYROTROPIN BLOOD LEVEL; TUMOR CELL;

ALLELES; ANIMALS; CARCINOMA; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; MICE; MUTAGENESIS, SITE-DIRECTED; MUTATION; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID HORMONE RECEPTORS BETA; THYROID HORMONES; THYROID NEOPLASMS; THYROTROPIN;

EID: 84866759782     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1600     Document Type: Article

References (43)

1. Refetoff S, Weiss RE, Usala SJ 1993 The syndromes of resistance to thyroid hormone. Endocr Rev 14:348-399 (Pubitemid 23168055)
2. Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E, Weintraub BD 1995 Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med 123:572-583
3. Usala SJ, Menke JB, Watson TL, Wondisford FE, Weintraub BD, Bérard J, Bradley WE, Ono S, Mueller OT, Bercu BB 1991 A homozygous deletion in the c-erbA β thyroid hormone receptor gene in a patient with generalized thyroid hormone resistance: isolation and characterization of the mutant receptor. Mol Endocrinol 5:327-335 (Pubitemid 21923697)
4. Ono S, Schwartz ID, Mueller OT, Root AW, Usala SJ, Bercu BB 1991 Homozygosity for a dominant negative thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone. J Clin Endocrinol Metab 73:990-994 (Pubitemid 21901136)
5. Ferrara AM, Onigata K, Ercan O, Woodhead H, Weiss RE, Refetoff S 2012 Homozygous thyroid hormone receptor beta-gene mutations in resistance to thyroid hormone: three new cases and review of the literature. J Clin Endocrinol Metab 97:1328-1336
6. Yen PM, Chin WW 1994 Molecular mechanisms of dominant negative activity by nuclear hormone receptors. Mol Endocrinol 8:1450-1454 (Pubitemid 24370193)
7. Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter TA, Kazlauskaite R, Pankratz DG, Wynshaw-Boris A, Refetoff S, Weintraub B, Willingham MC, Barlow C, Cheng S 2000 Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci USA 97:13209-13214
8. Cheng SY 2004 New development in thyroid hormone resistance. Hot Thyroidology No 1
9. Parrilla R, Mixson AJ, McPherson JA, McClaskey JH, Weintraub BD 1991 Characterization of seven novel mutations of the c-erb Aßgene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain. J Clin Invest 88:2123-2130
10. Suzuki H, Willingham MC, Cheng SY 2002 Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12:963-969 (Pubitemid 35404130)
11. Furuya F, Hanover JA, Cheng SY 2006 Activation of phosphatidyl-inositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci USA 103:1780-1785 (Pubitemid 43228770)
12. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M 2001 Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61:6105-6111 (Pubitemid 32762546)
13. Ying H, Suzuki H, Zhao L, Willingham MC, Meltzer P, Cheng SY 2003 Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor γ during thyroid carcinogenesis. Cancer Res 63:5274-5280 (Pubitemid 37139841)
14. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, Cheng SY 2006 PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-κB signaling pathway. Oncogene 25:2736-2747
15. Ying H, Furuya F, Zhao L, Araki O, West BL, Hanover JA, Willingham MC, Cheng SY 2006 Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone β receptor inhibits mitotic progression. J Clin Invest 116:2972-2984 (Pubitemid 44684482)
16. Kim CS, Ying H, Willingham MC, Cheng SY 2007 The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis 28:932-939 (Pubitemid 47072175)
17. Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY 2008 Regulation of β-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol 28:4598-4608 (Pubitemid 351977757)
18. Lu C, Zhao L, Ying H, Willingham MC, Cheng SY 2010 Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology 151:1929-1939
19. Kim HK, Kim D, Yoo EH, Lee JI, Jang HW, Tan AH, Hur KY, Kim JH, Kim KW, Chung JH, Kim SW 2010 A case of resistance to thyroid hormone with thyroid cancer. J Korean Med Sci 25:1368-1371
20. Paragliola RM, Lovicu RM, Locantore P, Senes P, Concolino P, Capoluongo E, Pontecorvi A, Corsello SM 2011 Differentiated thyroid cancer in two patients with resistance to thyroid hormone. Thyroid 21:793-797
21. Weinert LS, Ceolin L, Romitti M, Camargo EG, Maia AL 2012 Is there a role for inherited TRβ mutation in human carcinogenesis? Arq Bras Endocrinol Metab 56:67-71
22. Zhu XG, Zhao L, Willingham MC, Cheng SY 2010 Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma. Oncogene 29:1909-1919
23. Lin KH, Willingham MC, Liang CM, Cheng SY 1991 Intracellular distribution of the endogenous and transfected β form of thyroid hormone nuclear receptor visualized by the use of domain-specific monoclonal antibodies. Endocrinology 128:2601-2609
24. Zhao X, Guan JL 2011 Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev 63:610-615
25. Guan JL 2010 Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer. IUBMB Life 62:268-276
26. Kim LC, Song L, Haura EB 2009 Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6:587-595
27. Schlaepfer DD, Hunter T 1996 Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases. Mol Cell Biol 16:5623-5633 (Pubitemid 26315082)
28. Brunton VG, Frame MC 2008 Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 8:427-432
29. Zachary I 1997 Focal adhesion kinase. Int J Biochem Cell Biol 29:929-934 (Pubitemid 27478877)
30. Cukierman E, Pankov R, Stevens DR, Yamada KM 2001 Taking cell-matrix adhesions to the third dimension. Science 294:1708-1712 (Pubitemid 33104840)
31. Hehlgans S, Haase M, Cordes N 2007 Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775:163-180 (Pubitemid 44881199)
32. Chatzizacharias NA, Kouraklis GP, Theocharis SE 2008 Clinical significance of FAK expression in human neoplasia. Histol Histopathol 23:629-650 (Pubitemid 351552349)
33. Furumoto H, Ying H, Chandramouli GV, Zhao L, Walker RL, Meltzer PS, Willingham MC, Cheng SY 2005 An unliganded thyroid hormone β receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol 25:124-135 (Pubitemid 40039805)
34. Méndez-Pertuz M, Sánchez-Pacheco A, Aranda A 2003 The thyroid hormone receptor antagonizes CREB-mediated transcription. EMBO J 22:3102-3112 (Pubitemid 36758630)
35. Ying H, Suzuki H, Furumoto H, Walker R, Meltzer P, Willingham MC, Cheng SY 2003 Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis 24:1467-1479 (Pubitemid 37160837)
36. Lu C, Cheng SY 2011 Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis. Steroids 76:885-891
37. Lu C, Mishra A, Zhu YJ, Meltzer P, Cheng SY 2011 Global expression profiling reveals gain-of-function oncogenic activity of a mutated thyroid hormone receptor in thyroid carcinogenesis. Am J Cancer Res 1:168-191
38. Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H 2009 Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) 71:434-439
39. Boelaert K 2009 The association between serum TSH concentration and thyroid cancer. Endocr Relat Cancer 16:1065-1072
40. Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Coscio G, Berti P, Grasso L, Elisei R, Pinchera A, Vitti P 2009 Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer 16:1251-1260
41. Fiore E, Vitti P 2012 Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 97:1134-1145
42. Cheng SY 2007 Thyroid hormone receptor mutations and disease: insights from knock-in mouse models. Expert Rev Endocrinol Metab 2:47-57
43. Cheng SY 2004 Multi-factorial regulation of in vivo action of TRßmutants. Lessons learned from RTH mice with a targeted mutation in the TRβ gene. In: Beck-Peccoz P, ed. Syndromes of hormone resistance in the hypothalamic-pituitary-thyroid axis. London: Kluwer; Academic Publishers 137-148